CathWork's FFRangio System gets nod in Japan

By staff writers

October 6, 2022 -- The Japanese Pharmaceuticals and Medical Devices Agency has cleared the latest version of CathWork's FFRangio System for diagnosing functional ischemia in patients with ischemic coronary artery disease.

The fourth-generation system includes significant automation and enhancements while offering the same 93% diagnostic accuracy for measuring fractional flow reserve (FFR) compared with invasive wire-derived FFR, according to the company.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking